Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Prospective, Open-Label, Single-Arm, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

NCT06754085 is registered in ClinicalTrials.gov with HTA Co., Ltd. as lead sponsor.

NCT NCT06754085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06754085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Prospective, Open-Label, Single-Arm, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Lead sponsor
HTA Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 19, 2024
Completion date
June 11, 2026
Enrollment
131 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer